<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30652744</article-id><article-id pub-id-type="pmc">6326433</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0137</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Negative Effect of Mean Perfusion Pressure on the Development of
Acute Kidney Injury after Transcatheter Aortic Valve
Implantation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>G&#x000fc;l</surname><given-names>Ilker</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Cerit</surname><given-names>Levent</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Senturk</surname><given-names>Bihter</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Zungur</surname><given-names>Mustafa</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Alkan</surname><given-names>Mustafa Beyaz&#x00131;t</given-names></name><xref ref-type="aff" rid="aff4">4</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Kemal</surname><given-names>Hatice</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Cerit</surname><given-names>Zeynep</given-names></name><xref ref-type="aff" rid="aff5">5</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Yaman</surname><given-names>Belma</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Usalp</surname><given-names>Songul</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Duygu</surname><given-names>Hamza</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Near East University, Faculty of Medicine, Department of
Cardiology, Nicosia, Cyprus. </aff><aff id="aff2">
<label>2</label> Dokuz Eyl&#x000fc;l University, Faculty of Medicine, Department of
Cardiology, Izmir, Turkey. </aff><aff id="aff3">
<label>3</label> Kent Hospital, Cardiology Clinic, Izmir, Turkey. </aff><aff id="aff4">
<label>4</label> Kas State Hospital, Antalya, Turkey. </aff><aff id="aff5">
<label>5</label> Near East University, Faculty of Medicine, Department of Pediatric
Cardiology, Nicosia, Cyprus. </aff><author-notes><corresp id="c1">Correspondence Address: Levent Cerit, Near East University
Hospital, Near East Boulevard, Nicosia, Cyprus - Zip Code: 99138. E-mail:
<email>drcerit@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Nov-Dec</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2018</year></pub-date><volume>33</volume><issue>6</issue><fpage>559</fpage><lpage>566</lpage><history><date date-type="received"><day>02</day><month>4</month><year>2018</year></date><date date-type="accepted"><day>29</day><month>5</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To evaluate the predictive value of mean perfusion pressure (mPP) in the
development of acute kidney injury (AKIN) after transcatheter aortic valve
implantation (TAVI).</p></sec><sec><title>Methods</title><p>One hundred and forty seven consecutive patients with aortic stenosis (AS)
were evaluated for this study and 133 of them were included. Mean arterial
pressure (mAP) and central venous pressure (CVP) were used to calculate mPP
before TAVI procedure (mPP = mAP-CVP). The occurrence of AKIN was evaluated
with AKIN classification according to the Valve Academic Research
Consortium-2 recommendations. The patients were divided into two groups
according to the receiver operating characteristic (ROC) analysis of their
mPP levels (high-risk group and low-risk group).</p></sec><sec><title>Results</title><p>The AKIN prevalence was 22.6% in this study population. Baseline serum
creatinine level, glomerular filtration rate, amount of contrast medium, and
the level of mPP were determined as predictive factors for the development
of AKIN.</p></sec><sec><title>Conclusion</title><p>The occurrence of AKIN is associated with increased morbidity and mortality
rates in patients with TAVI. In addition to the amount of contrast medium
and basal kidney functions, our study showed that lower mPP was strongly
associated with development of AKIN after TAVI.</p></sec></abstract><kwd-group><kwd>Transcatheter Aortic Valve Replacement</kwd><kwd>Kidney</kwd><kwd>Acute Kidney Injury</kwd><kwd>Perfusion</kwd></kwd-group></article-meta></front><body><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="35%" span="1"/><col width="05%" span="1"/><col width="10%" span="1"/><col width="40%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#eaeaea" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" colspan="2" style="background-color:#eaeaea" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>AKIN</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Acute kidney
injury</bold></td><td align="left" rowspan="1" colspan="1"><bold>&#x000a0;</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>GFR</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Glomerular
filtration rate</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>AR</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Aortic
regurgitation</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>HR-G</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= High-risk
group</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>AS</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Aortic
stenosis</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>LR-G</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Low-risk
group</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>AUC</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Area under the
curve</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>mAP</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Mean arterial
pressure</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>AVA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Aortic valve
area</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>mPP</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Mean perfusion
pressure</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CAD</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Coronary artery
disease</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>NRF</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Normal renal
functions</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CHF</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Congestive heart
failure</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>PCI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Percutaneous
coronary intervention</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Confidence
interval</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>RBC</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Red blood
cell</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CM</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Contrast
mediums</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ROC</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Receiver operating
characteristic</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>COPD</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Chronic
obstructive pulmonary disease</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>SAVR</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Surgical aortic
valve replacement</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CrCl</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Creatinine
clearance</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>SBP</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Systolic blood
pressure</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CVP</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Central venous
pressure</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>STS</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Society of
Thoracic Surgeons</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CT</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Computed
tomography</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>TAVI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Transcatheter
aortic valve implantation</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>DBP</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Diastolic blood
pressure</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>VARC-2</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Valve Academic
Research Consortium-2</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>DM</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Diabetes
mellitus</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Aortic stenosis (AS) is one of the most common cardiac degenerative valvular
diseases, with a prevalence of 3-5% in patients above 75 years of
age<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Surgical aortic valve replacement (SAVR) is
currently considered the gold standard treatment for severe symptomatic
AS<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.
Transcatheter aortic valve implantation (TAVI) has emerged as an alternative to
surgery for patients with severe symptomatic AS, particularly for those who were
considered at intermediate to high risk for surgery<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Since its introduction
in 2002, more than 200,000 patients have undergone TAVI globally.</p><p>Ageing, preexisting impaired kidney function, hemodynamic instability, congestive
heart failure (CHF), diabetes mellitus (DM), anaemia, and the usage of great amount
of contrast mediums (CM) are well-known risk factors for the development of acute
kidney injury (AKIN) after TAVI<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>Although these risk factors have been well known, the predictive value of mean
perfusion pressure (mPP) in the development of AKIN has not been investigated yet.
Therefore, in this study, we aimed to evaluate the predictive value of mPP in the
development of AKIN after TAVI.</p></sec><sec sec-type="methods"><title>METHODS</title><p>In this study, 147 consecutive patients who had undergone TAVI procedure in our
clinic between June 2013 and December 2015 were evaluated. One hundred and thirty
three of them met the inclusion criteria and were included in this study. Patients
who had invasive blood pressure monitorization, jugular venous catheter, and were
hemodynamically stable were included in our study. Patients who had undergone renal
replacement therapy, presented glomerular filtration rate (GFR) &#x0003c;30 ml/min/1.73
m<sup>2</sup>, had decompensated heart failure, received inotropic agents, had
intra-aortic balloon pump, and received CM within the last 48 hours were excluded.
Patients who had undergone additional procedures or received additional CM due to
vascular complications, and had chronic pulmonary diseases or chronic liver diseases
were also excluded from the study. Intravenous hydration therapy was started in
patients with GFR &#x0003c;50 ml/min/1.73 m<sup>2</sup> for 12 hours before the procedure
and continued for 24-48 hours after TAVI. Patients' daily blood tests including
creatinine were checked for three days before and three days after TAVI.</p><sec><title>Mean Perfusion Pressure</title><p>Blood pressure of every patient was monitored using invasive monitorization
during the 12 hours before TAVI procedure. Also during this period, mean
arterial pressure (mAP) calculated by monitors was entered in patient files.
Central venous pressure (CVP) was monitored with catheters implanted by
anesthesiologists in all patients before valve implantation. The mPP was
calculated using the formula MPP = mAP-CVP.</p></sec><sec><title>Acute Kidney Injury</title><p>The Valve Academic Research Consortium-2 (VARC-2) criteria were used to evaluate
any complication occuring in TAVI patients<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. VARC-2 recommends that the AKIN
system should be used to diagnose AKIN. According to the AKIN system:</p><p>
<list list-type="bullet"><list-item><p>AKIN Stage 1: Increase in serum creatinine of 150-199% (1.5-1.99
&#x000d7; increase compared with baseline) or increase of &#x02265;0.3
mg/dL (&#x02265;26.4 mmol/L) or urine output &#x0003c;0.5 mL/kg/h for
&#x0003e;6 h but &#x0003c;12 h;</p></list-item><list-item><p>AKIN Stage 2: Increase in serum creatinine of 200-299% (2.0-2.99
&#x000d7; increase compared with baseline) or urine output &#x0003c;0.5
mL/kg/h for &#x0003e;12 h but &#x0003c;24 h;</p></list-item><list-item><p>AKIN Stage 3: Increase in serum creatinine of &#x02265;300% (&#x0003e;3
&#x000d7; increase compared with baseline) or serum creatinine of
&#x02265;4.0 mg/dL (&#x02265;354 mmol/L) with an acute increase of at
least 0.5 mg/dL (44 mmol/L) or urine output &#x0003c;0.3 ml/kg/h for
&#x0003e;24 h or anuria for &#x0003e;12 h.</p></list-item></list>
</p></sec><sec><title>TAVI Procedure</title><p>Severe AS was diagnosed with echocardiographic methods. The situations of average
aortic gradient &#x0003e; 40 mmHg, aortic valve area (AVA) &#x0003c;1 cm<sup>2</sup>, and
valve area index (valve area/body surface area) &#x0003c;0.6 cm<sup>2</sup> were
considered to be severe AS<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. The balloon-expandable Edwards Sapien XT
valve (Edwards Lifesciences, Irvine, California, USA) was used for TAVI process.
Vascular occlusion device (ProStar XL, Abbott Laboratories, North Chicago,
Illinois, USA) was used in eligible patients in terms of femoral artery diameter
and anatomy. The surgical cut-down method was applied in patients who were
unsuitable for using iliac and femoral artery anatomy vascular closure device.
Transoesophageal echocardiography and multislice computed tomography (CT) tests
were done to determine the diameter of the aortic bioprosthesis implanted. In
all patients, clopidogrel 75 mg and acetylsalicylic acid 100 mg were started
before TAVI procedure. &#x00130;ohexol (Omnipaque, GE Healthcare), a nonionic
low-osmolar monomeric CM, was used as the opaque material. The amount of CM was
recorded during all TAVI procedure. Examinations such as CT and coronary
angiography that required administration of CM, except TAVI procedures, were
performed at least 72 hours before. Daily kidney function tests of all patients
were monitored in our centre from admission to discharge. Creatinine levels were
checked in the second week, and the first, third, sixth and twelfth month after
TAVI procedure (COBAS Integra 400 plus, Roche Diagnostics).</p><p>The patients were prospectively followed during one year after TAVI. The informed
consent form was obtained from each subject, and the study was conducted in
accordance with the Helsinki Declaration. The study protocol was approved by the
local ethics committee.</p></sec><sec><title>Study Groups</title><p>Based on the receiver operating characteristic (ROC) analysis, patients who had
lower mPP values (&#x0003c;72 mmHg), which was determined as the threshold value for
AKIN development, were included in the high-risk group (HR-G), and those who had
higher mPP values (&#x02265;72 mmHg) were included in the low-risk group (LR-G).
Additionally, characteristics of patients with normal renal functions (NRF) and
those who developed AKIN were evaluated.</p></sec><sec><title>Statistical Analysis</title><p>Statistical analysis was performed using SPSS 17.0 software (SPSS, Chicago,
Illinois, USA). The Kolmogorov-Smirnov test was used to assess the normality of
distributions. Variables not normally distributed were expressed as medians
(interquartile ranges). Normally distributed continuous variables were expressed
as a mean &#x000b1; standard deviation. The means for normally distributed
continuous variables were compared by independent-samples t-tests.
Skew-distributed continuous variables were compared using a Mann-Whitney U test.
Pearsons x<sup>2</sup> test and Fisher exact test were used to compare
categorical variables. Univariate analyses were performed with the variables,
such as age (years), left ventricular ejection fraction (%), mean aortic
gradient (mmHg), Society of Thoracic Surgeons (STS) score (%), logistic
EuroSCORE (%), mPP (mmHg), systolic blood pressure (SBP, mmHg), diastolic blood
pressure (DBP, mmHg), DM (%), hypertension (%), coronary artery disease (CAD,
%), creatinine (mg/dl), GFR (ml/dk/1.73 m<sup>2</sup>), amount of CM (ml),
pre-TAVI haemoglobin levels (g/dl), and red blood cell transfusion after TAVI
(%). The backward stepwise multivariate regression analysis was performed with
the variables of mPP, left ventricular ejection fraction, baseline creatinine,
GFR, red blood cell (RBC) transfusion, amount of CM, SBP, and DBP; the
<italic>P</italic> values of those was found to be
<italic>P</italic>&#x0003c;0.10, by univariate analyses. A ROC curve analysis was
performed to identify the optimal cut-off point of mPP to predict AKIN in
patients with severe AS. The area under the curve (AUC) values were calculated
as a measure of test accuracy. A two-sided <italic>P</italic>&#x0003c;0.05 was
considered significant within a 95% confidence interval (CI). Kaplan-Meier
survival plots were constructed from the index procedure and up to one year
after that and compared using the log-rank test. <italic>P</italic> values
&#x0003c;0.05 were accepted as statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Patients' General Characteristics</title><p>One hundred and thirty three patients (54.1% females; mean age of 78.1&#x000b1;7.5
years) were enrolled in this study. AKIN was recorded in 30 patients after TAVI
(22.6%). Mean values of SBP, DBP, mAP, and mPP were lower in HR-G and AKIN
groups. The mean value of CVP was higher in HR-G and AKIN groups. The average
mean gradient of the aortic valve was 49.7&#x000b1;11.7 mmHg, the mean AVA was
0.65&#x000b1;0.11 cm<sup>2</sup>, and the mean value of left ventricular ejection
fraction was 42 &#x000b1;14.7%.</p></sec><sec><title>Procedural Data</title><p>A balloon-expandable Edwards SAPIEN XT valve was implanted via transfemoral
access in all patients. The mean radiation time was 7.6&#x000b1;3.1 min. Mean CM
and duration of procedure were 143.4&#x000b1;22.7 ml and 69.2&#x000b1;28.1 min,
respectively. There weren't any significant difference between the two groups
according to the numbers and durations of the rapid ventricular pacing.</p></sec><sec><title>Mean Perfusion Pressure and Acute Kidney &#x00130;njury</title><p>The values of mPP were significantly lower in AKIN patients (65.9&#x000b1;9.5
<italic>vs</italic>. 76.3&#x000b1;7.4 <italic>P</italic>&#x0003c;0.001). Age,
gender, DM, hypertension, chronic obstructive pulmonary disease (COPD), CAD,
moderate to high grade aortic regurgitation (AR) after TAVI, risk scores for
TAVI, haemoglobin, cardiac systolic functions, mean aortic gradient, kidney
function tests, amount of CM, previous coronary bypass surgery, and percutaneous
coronary intervention (PCI) rates were similar between the two groups. SBP, DBP,
mAP, and mPP levels were significantly lower in HR-G group, but CVP level was
higher in HR-G group (<xref rid="t1" ref-type="table">Table 1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical, laboratory, echocardiographic, and angiographic characteristics
of the study population</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="30%" span="1"/><col width="23%" span="1"/><col width="24%" span="1"/><col width="24%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">HR-G (n=52)</th><th align="center" rowspan="1" colspan="1">LR-G (n=81)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">78.8&#x000b1;6.9</td><td align="center" rowspan="1" colspan="1">78.6&#x000b1;7.8</td><td align="center" rowspan="1" colspan="1">0.369</td></tr><tr><td align="left" rowspan="1" colspan="1">Female gender, n (%)</td><td align="center" rowspan="1" colspan="1">29 (55.8)</td><td align="center" rowspan="1" colspan="1">43 (53.1)</td><td align="center" rowspan="1" colspan="1">0.451</td></tr><tr><td align="left" rowspan="1" colspan="1">STS score (%)</td><td align="center" rowspan="1" colspan="1">13.3&#x000b1;4.3</td><td align="center" rowspan="1" colspan="1">14.6&#x000b1;6.7</td><td align="center" rowspan="1" colspan="1">0.472</td></tr><tr><td align="left" rowspan="1" colspan="1">Logistic EuroSCORE (%)</td><td align="center" rowspan="1" colspan="1">29.4 (15.9-38.2)</td><td align="center" rowspan="1" colspan="1">24.7 (14.8-35.3)</td><td align="center" rowspan="1" colspan="1">0.093</td></tr><tr><td align="left" rowspan="1" colspan="1">AKIN, n (%)</td><td align="center" rowspan="1" colspan="1">22 (42.3)</td><td align="center" rowspan="1" colspan="1">8 (9.9)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Mortality, n (%)</td><td align="center" rowspan="1" colspan="1">5 (9.6)</td><td align="center" rowspan="1" colspan="1">3 (3.7)</td><td align="center" rowspan="1" colspan="1">0.153</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (g/dl)</td><td align="center" rowspan="1" colspan="1">12.3&#x000b1;1.6</td><td align="center" rowspan="1" colspan="1">12.4&#x000b1;1.8</td><td align="center" rowspan="1" colspan="1">0.860</td></tr><tr><td align="left" rowspan="1" colspan="1">RBC transfusion, n (%)</td><td align="center" rowspan="1" colspan="1">15 (28.8)</td><td align="center" rowspan="1" colspan="1">20 (24.7)</td><td align="center" rowspan="1" colspan="1">0.785</td></tr><tr><td align="left" rowspan="1" colspan="1">Left ventricle ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">41.9&#x000b1;10.4</td><td align="center" rowspan="1" colspan="1">42.6&#x000b1;11.1</td><td align="center" rowspan="1" colspan="1">0.726</td></tr><tr><td align="left" rowspan="1" colspan="1">NT-pro BNP (pg/ml)</td><td align="center" rowspan="1" colspan="1">4188&#x000b1;1388</td><td align="center" rowspan="1" colspan="1">3811&#x000b1;1258</td><td align="center" rowspan="1" colspan="1">0.640</td></tr><tr><td align="left" rowspan="1" colspan="1">AVA (cm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">0.65&#x000b1;0.19</td><td align="center" rowspan="1" colspan="1">0.64&#x000b1;0.21</td><td align="center" rowspan="1" colspan="1">0.506</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean gradient (mmHg)</td><td align="center" rowspan="1" colspan="1">49.1&#x000b1;12.9</td><td align="center" rowspan="1" colspan="1">50.2&#x000b1;10.6</td><td align="center" rowspan="1" colspan="1">0.590</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">120.1&#x000b1;9.8</td><td align="center" rowspan="1" colspan="1">132.7&#x000b1;7.3</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">57.4&#x000b1;8.1</td><td align="center" rowspan="1" colspan="1">69.6&#x000b1;9.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">mAP (mmHg)</td><td align="center" rowspan="1" colspan="1">78.1&#x000b1;9.7</td><td align="center" rowspan="1" colspan="1">90.5&#x000b1;8.3</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CVP (mmHg)</td><td align="center" rowspan="1" colspan="1">13.2&#x000b1;2.9</td><td align="center" rowspan="1" colspan="1">10.9&#x000b1;2.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">mPP (mmHg)</td><td align="center" rowspan="1" colspan="1">64.1&#x000b1;7.1</td><td align="center" rowspan="1" colspan="1">79.7&#x000b1;5.3</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dl)</td><td align="center" rowspan="1" colspan="1">1.06&#x000b1;0.32</td><td align="center" rowspan="1" colspan="1">1.01&#x000b1;0.29</td><td align="center" rowspan="1" colspan="1">0.642</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR (ml/dk/1.73 m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">60.15&#x000b1;14.6</td><td align="center" rowspan="1" colspan="1">62.69&#x000b1;16.7</td><td align="center" rowspan="1" colspan="1">0.348</td></tr><tr><td align="left" rowspan="1" colspan="1">Diuretic, n (%)</td><td align="center" rowspan="1" colspan="1">10 (19.2)</td><td align="center" rowspan="1" colspan="1">13 (16.0)</td><td align="center" rowspan="1" colspan="1">0.443</td></tr><tr><td align="left" rowspan="1" colspan="1">RAAS blocker, n (%)</td><td align="center" rowspan="1" colspan="1">24 (46.2)</td><td align="center" rowspan="1" colspan="1">40 (49.4)</td><td align="center" rowspan="1" colspan="1">0.214</td></tr><tr><td align="left" rowspan="1" colspan="1">Beta-blocker, n (%)</td><td align="center" rowspan="1" colspan="1">29 (55.7)</td><td align="center" rowspan="1" colspan="1">50 (61.7)</td><td align="center" rowspan="1" colspan="1">0.494</td></tr><tr><td align="left" rowspan="1" colspan="1">Amount of contrast (ml)</td><td align="center" rowspan="1" colspan="1">147 (115-245)</td><td align="center" rowspan="1" colspan="1">140.5 (120-212)</td><td align="center" rowspan="1" colspan="1">0.065</td></tr><tr><td align="left" rowspan="1" colspan="1">AR after TAVI (&#x02265; grade II)</td><td align="center" rowspan="1" colspan="1">6 (11.5)</td><td align="center" rowspan="1" colspan="1">10 (12.3)</td><td align="center" rowspan="1" colspan="1">0.646</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of rapid pacing</td><td align="center" rowspan="1" colspan="1">2.9&#x000b1;0.6</td><td align="center" rowspan="1" colspan="1">2.7&#x000b1;0.4</td><td align="center" rowspan="1" colspan="1">0.348</td></tr><tr><td align="left" rowspan="1" colspan="1">Rapid pacing duration (second)</td><td align="center" rowspan="1" colspan="1">41 (25-63)</td><td align="center" rowspan="1" colspan="1">40 (21-55)</td><td align="center" rowspan="1" colspan="1">0.642</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous CABG, n (%)</td><td align="center" rowspan="1" colspan="1">10 (19.2)</td><td align="center" rowspan="1" colspan="1">13 (16.0)</td><td align="center" rowspan="1" colspan="1">0.443</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous PCI, n (%)</td><td align="center" rowspan="1" colspan="1">9 (17.3)</td><td align="center" rowspan="1" colspan="1">19 (23.8)</td><td align="center" rowspan="1" colspan="1">0.254</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td align="center" rowspan="1" colspan="1">19 (36.5)</td><td align="center" rowspan="1" colspan="1">27 (33.3)</td><td align="center" rowspan="1" colspan="1">0.422</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension, n (%)</td><td align="center" rowspan="1" colspan="1">21 (40.6)</td><td align="center" rowspan="1" colspan="1">34 (41.9)</td><td align="center" rowspan="1" colspan="1">0.908</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypercholesterolemia, n (%)</td><td align="center" rowspan="1" colspan="1">20 (38.5)</td><td align="center" rowspan="1" colspan="1">40 (49.4)</td><td align="center" rowspan="1" colspan="1">0.145</td></tr><tr><td align="left" rowspan="1" colspan="1">COPD, n (%)</td><td align="center" rowspan="1" colspan="1">20 (38.5)</td><td align="center" rowspan="1" colspan="1">26 (32,1)</td><td align="center" rowspan="1" colspan="1">0.285</td></tr><tr><td align="left" rowspan="1" colspan="1">CAD, n (%)</td><td align="center" rowspan="1" colspan="1">25 (48.1)</td><td align="center" rowspan="1" colspan="1">40 (49.4)</td><td align="center" rowspan="1" colspan="1">0.512</td></tr><tr><td align="left" rowspan="1" colspan="1">Intensive care unit (days)</td><td align="center" rowspan="1" colspan="1">2 (1.3-3.2)</td><td align="center" rowspan="1" colspan="1">1.5 (1.1-2.1)</td><td align="center" rowspan="1" colspan="1">0.022</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital duration (days)</td><td align="center" rowspan="1" colspan="1">5 (3.5-6.2)</td><td align="center" rowspan="1" colspan="1">4 (3.3-5.8)</td><td align="center" rowspan="1" colspan="1">0.027</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><p>Values are number (%), mean &#x000b1; standard deviation, or median
[25<sup>th</sup>, 75<sup>th</sup> percentiles].</p></fn><fn id="TFN02"><p>AKIN=acute kidney injury; AR=aortic regurgitation; AVA=aortic valve
area; BNP=b-type natriuretic peptide; CABG=coronary artery bypass
graft; CAD=coronary artery disease; COPD=chronic obstructive
pulmonary disease; CVP=central venous pressure; DBP=diastolic blood
pressure; eGFR=estimated glomerular filtration rate; HR-G=High-risk
group; LR-G=Low-risk group; mAP=mean arterial pressure; mPP=mean
perfusion pressure; NT=N-terminal; PCI=percutaneous coronary
intervention; RAAS=renin-angiotensin-aldosterone system; RBC=red
blood cell; SBP=systolic blood pressure; STS=Society of Thoracic
Surgeons; TAVI=transcatheter aortic valve implantation</p></fn></table-wrap-foot></table-wrap></sec><sec><title>AKI and Risk Factors</title><p>There was no significant difference between AKIN and NRF groups in terms of CAD,
DM, hypertension, and COPD. The AKIN group had longer hospitalisation duration
(5.5 <italic>vs</italic>. 4 days, <italic>P</italic>=0.014). After TAVI
procedure, 2 (2.2%) patients needed permanent pacemaker implantation due to
atrioventricular conduction block. Transfusion rates were higher in the AKIN
group (13 <italic>vs</italic>. 22, <italic>P</italic>=0.032). Patients in AKIN
and NRF groups did not show a significant difference in terms of diuretic,
renin-angiotensin-aldosterone blocker, and beta-blocker therapy (<xref rid="t1" ref-type="table">Table 1</xref>). The amount of CM was
significantly higher in the AKIN group (148 <italic>vs</italic>. 138 ml,
<italic>P</italic>=0.028). Eight patients died during the study period.
Total mortality was higher in the AKIN group than in the NRF group (16.6%
<italic>vs</italic>. 2.9%, <italic>P</italic>=0.015; <xref rid="t2" ref-type="table">Table 2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline characteristics in patients with or without AKIN (NRF
group).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="30%" span="1"/><col width="23%" span="1"/><col width="24%" span="1"/><col width="24%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">AKIN group (n=30)</th><th align="center" rowspan="1" colspan="1">NRF (n=103)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">78.2&#x000b1;7.3</td><td align="center" rowspan="1" colspan="1">77.6&#x000b1;8.1</td><td align="center" rowspan="1" colspan="1">0.699</td></tr><tr><td align="left" rowspan="1" colspan="1">Female gender, n (%)</td><td align="center" rowspan="1" colspan="1">14 (46.7)</td><td align="center" rowspan="1" colspan="1">58 (56.3)</td><td align="center" rowspan="1" colspan="1">0.234</td></tr><tr><td align="left" rowspan="1" colspan="1">STS score (%)</td><td align="center" rowspan="1" colspan="1">14.4&#x000b1;5.3</td><td align="center" rowspan="1" colspan="1">13.2&#x000b1;5.7</td><td align="center" rowspan="1" colspan="1">0.154</td></tr><tr><td align="left" rowspan="1" colspan="1">Logistic EuroSCORE (%)</td><td align="center" rowspan="1" colspan="1">27.5 (14.7-36.1)</td><td align="center" rowspan="1" colspan="1">26.5 (15.0-37.1)</td><td align="center" rowspan="1" colspan="1">0.742</td></tr><tr><td align="left" rowspan="1" colspan="1">Mortality, n (%)</td><td align="center" rowspan="1" colspan="1">5 (16.6)</td><td align="center" rowspan="1" colspan="1">3 (2.9)</td><td align="center" rowspan="1" colspan="1">0.015</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (g/dl)</td><td align="center" rowspan="1" colspan="1">11.1&#x000b1;1.7</td><td align="center" rowspan="1" colspan="1">11.3&#x000b1;1.8</td><td align="center" rowspan="1" colspan="1">0.716</td></tr><tr><td align="left" rowspan="1" colspan="1">RBC transfusion,&#x000a0; n (%)</td><td align="center" rowspan="1" colspan="1">13 (43.3)</td><td align="center" rowspan="1" colspan="1">22 (21.4)</td><td align="center" rowspan="1" colspan="1">0.032</td></tr><tr><td align="left" rowspan="1" colspan="1">Left ventricle ejection fraction, %</td><td align="center" rowspan="1" colspan="1">41.9&#x000b1;10.4</td><td align="center" rowspan="1" colspan="1">42.6&#x000b1;11.1</td><td align="center" rowspan="1" colspan="1">0.245</td></tr><tr><td align="left" rowspan="1" colspan="1">NT-pro BNP (pg/ml)</td><td align="center" rowspan="1" colspan="1">4315&#x000b1;1492</td><td align="center" rowspan="1" colspan="1">3656&#x000b1;1168</td><td align="center" rowspan="1" colspan="1">0.524</td></tr><tr><td align="left" rowspan="1" colspan="1">AVA (cm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">0.61&#x000b1;0.22</td><td align="center" rowspan="1" colspan="1">0.68&#x000b1;0.28</td><td align="center" rowspan="1" colspan="1">0.605</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean gradient (mmHg)</td><td align="center" rowspan="1" colspan="1">51.5&#x000b1;13.8</td><td align="center" rowspan="1" colspan="1">49.2&#x000b1;10.8</td><td align="center" rowspan="1" colspan="1">0.355</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">121.9&#x000b1;10.6</td><td align="center" rowspan="1" colspan="1">129.5&#x000b1;9.7</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">57.8&#x000b1;8.1</td><td align="center" rowspan="1" colspan="1">66.9&#x000b1;7.7</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">mAP (mmHg)</td><td align="center" rowspan="1" colspan="1">79.5&#x000b1;7.8</td><td align="center" rowspan="1" colspan="1">87.5&#x000b1;6.9</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CVP (mmHg)</td><td align="center" rowspan="1" colspan="1">13.6&#x000b1;3.2</td><td align="center" rowspan="1" colspan="1">11.2&#x000b1;2.6</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">mPP (mmHg)</td><td align="center" rowspan="1" colspan="1">65.9&#x000b1;9.5</td><td align="center" rowspan="1" colspan="1">76.3&#x000b1;7.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dl)</td><td align="center" rowspan="1" colspan="1">1.17&#x000b1;0.36</td><td align="center" rowspan="1" colspan="1">0.99&#x000b1;0.26</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR (ml/dk/1.73 m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">53.4&#x000b1;15.0</td><td align="center" rowspan="1" colspan="1">64.1&#x000b1;15.4</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Diuretic, n (%)</td><td align="center" rowspan="1" colspan="1">8 (26.7)</td><td align="center" rowspan="1" colspan="1">15 (14.6)</td><td align="center" rowspan="1" colspan="1">0.548</td></tr><tr><td align="left" rowspan="1" colspan="1">RAAS blocker, n (%)</td><td align="center" rowspan="1" colspan="1">16 (53.3)</td><td align="center" rowspan="1" colspan="1">48 (46.6)</td><td align="center" rowspan="1" colspan="1">0.214</td></tr><tr><td align="left" rowspan="1" colspan="1">Beta-blocker, n (%)</td><td align="center" rowspan="1" colspan="1">18 (60.0)</td><td align="center" rowspan="1" colspan="1">51 (49.5)</td><td align="center" rowspan="1" colspan="1">0.406</td></tr><tr><td align="left" rowspan="1" colspan="1">Amount of contrast (ml)</td><td align="center" rowspan="1" colspan="1">148 (114-258)</td><td align="center" rowspan="1" colspan="1">138 (120-225)</td><td align="center" rowspan="1" colspan="1">0.028</td></tr><tr><td align="left" rowspan="1" colspan="1">AR after TAVI (&#x02265; grade II), n (%)</td><td align="center" rowspan="1" colspan="1">5 (16.7)</td><td align="center" rowspan="1" colspan="1">11 (10.7)</td><td align="center" rowspan="1" colspan="1">0.646</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of rapid ventricular pacing, n</td><td align="center" rowspan="1" colspan="1">3&#x000b1;0.8</td><td align="center" rowspan="1" colspan="1">2.7&#x000b1;0.4</td><td align="center" rowspan="1" colspan="1">0.442</td></tr><tr><td align="left" rowspan="1" colspan="1">Rapid pacing duration (second)</td><td align="center" rowspan="1" colspan="1">43 (26-67)</td><td align="center" rowspan="1" colspan="1">40.5 (22-53)</td><td align="center" rowspan="1" colspan="1">0.721</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous CABG, n (%)</td><td align="center" rowspan="1" colspan="1">7 (23.3)</td><td align="center" rowspan="1" colspan="1">16 (15.5)</td><td align="center" rowspan="1" colspan="1">0.143</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous PCI, n (%)</td><td align="center" rowspan="1" colspan="1">8 (26.7)</td><td align="center" rowspan="1" colspan="1">20 (19.4)</td><td align="center" rowspan="1" colspan="1">0.254</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td align="center" rowspan="1" colspan="1">10 (33.3)</td><td align="center" rowspan="1" colspan="1">36 (35.0)</td><td align="center" rowspan="1" colspan="1">0.527</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension, n (%)</td><td align="center" rowspan="1" colspan="1">11 (36.7)</td><td align="center" rowspan="1" colspan="1">44 (42.7)</td><td align="center" rowspan="1" colspan="1">0.174</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypercholesterolemia, n (%)</td><td align="center" rowspan="1" colspan="1">11 (36.7)</td><td align="center" rowspan="1" colspan="1">49 (47.6)</td><td align="center" rowspan="1" colspan="1">0.199</td></tr><tr><td align="left" rowspan="1" colspan="1">COPD, n (%)</td><td align="center" rowspan="1" colspan="1">12 (40.0)</td><td align="center" rowspan="1" colspan="1">34 (33.0)</td><td align="center" rowspan="1" colspan="1">0.309</td></tr><tr><td align="left" rowspan="1" colspan="1">CAD, n (%)</td><td align="center" rowspan="1" colspan="1">14 (46.7)</td><td align="center" rowspan="1" colspan="1">51 (49.5)</td><td align="center" rowspan="1" colspan="1">0.424</td></tr><tr><td align="left" rowspan="1" colspan="1">Intensive care unit (days)</td><td align="center" rowspan="1" colspan="1">2 (1.3-3.4)</td><td align="center" rowspan="1" colspan="1">1.5 (1.1-1.8)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital duration (days)</td><td align="center" rowspan="1" colspan="1">5.5 (3.4-6.8)</td><td align="center" rowspan="1" colspan="1">4 (3.1-5.2)</td><td align="center" rowspan="1" colspan="1">0.014</td></tr></tbody></table><table-wrap-foot><fn id="TFN03"><p>Values are number (%), mean &#x000b1; standard deviation, or median
[25<sup>th</sup>, 75<sup>th</sup> percentiles].</p></fn><fn id="TFN04"><p>AKIN=acute kidney injury; AR=aortic regurgitation; AVA=aortic valve
area; BNP=b-type natriuretic peptide; CABG=coronary artery bypass
graft; CAD=coronary artery disease; COPD=chronic obstructive
pulmonary disease; CVP=central venous pressure; DBP=diastolic blood
pressure; eGFR=estimated glomerular filtration rate; HR-G=High-risk
group; LR-G=Low-risk group; mAP=mean arterial pressure; mPP=mean
perfusion pressure; NT=N-terminal; PCI=percutaneous coronary
intervention; RAAS=renin-angiotensin-aldosterone system; RBC=red
blood cell; SBP=systolic blood pressure; STS=Society of Thoracic
Surgeons; TAVI=transcatheter aortic valve implantation</p></fn></table-wrap-foot></table-wrap></sec><sec><title>AKIN Predictors and Survival</title><p>In univariate analysis, mPP, left ventricle ejection fraction, baseline
creatinine, GFR, red blood cell transfusion, amount of CM, SBP, and DBP were
found to be significantly associated with AKIN <italic>(P</italic>&#x0003c;0.01 for
all parameters). Thus, the multivariate regression analysis was performed with
these variables; baseline creatinine, baseline GFR, amount of CM, and mPP were
found to be significant predictors of AKIN (<xref rid="t3" ref-type="table">Table 3</xref>). The ROC analysis of the significant variables in
multivariate regression analysis revealed that the cut-off value of mPP was 72
mmHg to predict the development of AKIN (AUC, 0.813; 95% CI, 0.721-0.905;
sensitivity, 72%; specificity, 84%; <xref ref-type="fig" rid="f1">Figure
1</xref>). Mortality rates were significantly higher in AKIN patients.
Kaplan-Meier survival curves for patients with and without AKIN (NRF group)
showed a significantly lower survival rate up to 1 year in the overall AKIN
group (16.6% <italic>vs</italic>. 0.03% log-rank, <italic>P</italic>=0.02; <xref ref-type="fig" rid="f2">Figure 2</xref>).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Results of multivariate regression analysis for predictors of post-TAVI
AKIN.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="30%" span="1"/><col width="23%" span="1"/><col width="24%" span="1"/><col width="24%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Odds ratio</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">mPP (mmHg)</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">2.7-8.5</td><td align="center" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" rowspan="1" colspan="1">Amount of contrast (ml)</td><td align="center" rowspan="1" colspan="1">7.0</td><td align="center" rowspan="1" colspan="1">3.2-11.1</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">RBC transfusion, n</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1">0.3-1.4</td><td align="center" rowspan="1" colspan="1">0.385</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline creatinine (mg/dl)</td><td align="center" rowspan="1" colspan="1">2.1</td><td align="center" rowspan="1" colspan="1">1.1-3.3</td><td align="center" rowspan="1" colspan="1">0.044</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline GFR (ml/min/1.73 m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">1.4-4.1</td><td align="center" rowspan="1" colspan="1">0.032</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">0.5</td><td align="center" rowspan="1" colspan="1">0.2-1.1</td><td align="center" rowspan="1" colspan="1">0.782</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">0.6</td><td align="center" rowspan="1" colspan="1">0.4-1.1</td><td align="center" rowspan="1" colspan="1">0.582</td></tr><tr><td align="left" rowspan="1" colspan="1">Left ventricle ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">1.3</td><td align="center" rowspan="1" colspan="1">0.7-2.0</td><td align="center" rowspan="1" colspan="1">0.248</td></tr></tbody></table><table-wrap-foot><fn id="TFN05"><p>AKIN=acute kidney injury; CI=confidence interval; DBP=diastolic blood
pressure; GFR=glomerular filtration rate; mPP=mean perfusion
pressure; RBC=red blood cell; SBP=systolic blood pressure;
TAVI=transcatheter aortic valve implantation</p></fn></table-wrap-foot></table-wrap><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>ROC curve of mean perfusion pressure. The mean perfusion pressure
value which can predict the acute kidney injury development was
determined as 72 mmHg in ROC analysis [AUC: 0.813 (95% CI;
0.721-0.905); sensitivity, 72%; specificity, 84%]. AUC = area under
the curve; CI = confidence interval; ROC = receiver operating
characteristics.</p></caption><graphic xlink:href="rbccv-33-06-0559-g01"/></fig>
</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Kaplan-Meier curves for overall survival in AKIN and non-AKIN (NRF)
groups. AKIN = acute kidney injury; NRF = normal renal
functions.</p></caption><graphic xlink:href="rbccv-33-06-0559-g02"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In our study, we found out that baseline creatinine, GFR, amount of CM, and lower mPP
values were significantly associated with the development of AKIN in patients with
TAVI.</p><p>Development of AKIN is strongly associated with increased major adverse cardiac
events after TAVI procedure<sup>[<xref rid="r9" ref-type="bibr">9</xref>-<xref rid="r11" ref-type="bibr">11</xref>]</sup>. While 40% of the patients suffer from AKIN after
SAVR, prevalence of AKIN ranges from 3.4% to 57% after TAVI
procedure<sup>[<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref>]</sup>. In accordance with previous studies, in our study
33 (21.2%) patients developed AKIN after TAVI. Excessive CM usage, hypotension,
rapid ventricular pacing, balloon aortoplasty, valve implantation, and embolisation
of aortic plaque are considered intra-operative risk factors for AKIN after
TAVI<sup>[<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p>As it is well known, CM reduce oxygen availability to the renal medulla and cause
renal ischemia<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. Several studies demonstrated that CM/GFR and
CM/creatinine clearance (CrCl) rates in invasive procedures are predictors of renal
failure<sup>[<xref rid="r16" ref-type="bibr">16</xref>-<xref rid="r18" ref-type="bibr">18</xref>]</sup>. It can be useful to calculate basal GFR and CrCl
before TAVI, to be used to calculate upper limits for CM. The mAP might be decreased
below 50 mmHg during rapid ventricular pacing. These hypotensive stages can
contribute to the development of AKIN. Therefore, number and duration of rapid
ventricular pacing used for our patients during TAVI were recorded in our study.
Although basal kidney function tests are important for impairment of renal function,
other factors, such as mPP, amount of CM, and rapid ventricular pacing, should be
kept in mind to predict renal impairment.</p><p>In addition to many factors affecting the development of AKIN, hemodynamic parameters
of patients before an invasive procedure are also important indicators of potential
renal complications. Renal hypoperfusion is the most important cause of AKIN after
SAVR and TAVI<sup>[<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup>. Renal perfusion pressure is the most important
predictor of renal blood flow. A normal renal perfusion pressure should be between
60 and 100 mmHg<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>. However, there isn't any non-invasive method that
can directly measure it. Renal perfusion pressure can be estimated using mPP, mAP,
and CVP levels. Especially, mPP calculated with mAP and CBP is shown to be an
important indicator for the continuation of NRF<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. A strong association
has been demonstrated between mPP levels and GFR in various
diseases<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>. Based on the study results, mPP values obtained
with invasive monitorization in advanced AS patients were found to be a significant
factor in predicting the development of AKIN. The predictive value of AKIN
development was calculated as 72 mmHg using ROC analysis (<xref ref-type="fig" rid="f1">Figure 1</xref>). The percentage of AKIN was much higher in the HR-G
group (42.3% <italic>vs</italic>. 9.9%, <italic>P</italic>&#x0003c;0.001). The
calculation of mPP is based on the difference between mAP and CVP. Since mAP values
of the HR-G group were lower and CVP values were higher, mPP values in this group
were low (<xref rid="t1" ref-type="table">Table 1</xref>). The value of mPP is more
closely associated with renal perfusion pressure, compared to mAP and
CVP<sup>[<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r22" ref-type="bibr">22</xref>]</sup>.</p><sec><title>Limitations of the Study</title><p>The main limitation of this study is the small number of patients included.
Additional information can be obtained in longer follow-up periods. In our
study, TAVI using balloon expandable prosthesis was performed, and it would be
useful to conduct similar studies with a self-expandable prosthesis.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>These findings led to the conclusion that among the patients with similar renal
functions, who received a similar amount of CM, those with lower mPP are at higher
risk for AKIN development. A model was created with regression analysis to identify
the factors affecting the development of AKIN in our study.</p><p>The mortality rate in patients who developed AKIN after TAVI ranges from 7.8% to
29%<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup>. In our study, the one-year mortality rate was
16.7% in patients who developed AKIN and 2.9% in patients who did not. The presence
of AKIN increased the mortality in a one-year period approximately by 5.5 times.
Therefore, preventing the development of AKIN should be an important goal to
minimise TAVI complications.</p><p>In our study, the amount of CM, basal kidney function tests, and lower mPP levels
(mPP &#x0003c;72 mmHg) were strongly associated with the development of AKIN after TAVI.
Further studies are needed to evaluate the association between mPP and AKIN in
patients treated with TAVI.</p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1"><bold>Authors&#x02019; roles &#x00026;
responsibilities</bold></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">IG</td><td align="left" rowspan="1" colspan="1">Analysis and interpretation of data; drafting the
paper; revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">LC</td><td align="left" rowspan="1" colspan="1">Analysis and interpretation of data; drafting the
paper; revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">BS</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">MZ</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">MBA</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">HK</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">ZC</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">BY</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">SU</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">HD</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Near East University Hospital, Near East Boulevard,
Nicosia, Cyprus.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eveborn</surname><given-names>GW</given-names></name><name><surname>Schirmer</surname><given-names>H</given-names></name><name><surname>Heggelund</surname><given-names>G</given-names></name><name><surname>Lunde</surname><given-names>P</given-names></name><name><surname>Rasmussen</surname><given-names>K</given-names></name></person-group><article-title>The evolving epidemiology of valvular aortic stenosis. The Tromso
study</article-title><source>Heart</source><year>2013</year><volume>99</volume><issue>6</issue><fpage>396</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">22942293</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>DH</given-names></name><name><surname>Popma</surname><given-names>JJ</given-names></name><name><surname>Reardon</surname><given-names>MJ</given-names></name><name><surname>Yakubov</surname><given-names>SJ</given-names></name><name><surname>Coselli</surname><given-names>JS</given-names></name><name><surname>Deeb</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Transcatheter aortic-valve replacement with a self-expanding
prosthesis</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><issue>19</issue><fpage>1790</fpage><lpage>1798</lpage><pub-id pub-id-type="pmid">24678937</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turina</surname><given-names>J</given-names></name><name><surname>Hess</surname><given-names>O</given-names></name><name><surname>Sepulcri</surname><given-names>F</given-names></name><name><surname>Krayenbuehl</surname><given-names>HP</given-names></name></person-group><article-title>Spontaneous course of aortic valve disease</article-title><source>Eur Heart J</source><year>1987</year><volume>8</volume><issue>5</issue><fpage>471</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">3609042</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cribier</surname><given-names>A</given-names></name></person-group><article-title>Development of transcatheter aortic valve implantation (TAVI): a
20-year odyssey</article-title><source>Arch Cardiovasc Dis</source><year>2012</year><volume>105</volume><issue>3</issue><fpage>146</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">22520797</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dangas</surname><given-names>G</given-names></name><name><surname>Iakovou</surname><given-names>I</given-names></name><name><surname>Nikolsky</surname><given-names>E</given-names></name><name><surname>Aymong</surname><given-names>ED</given-names></name><name><surname>Mintz</surname><given-names>GS</given-names></name><name><surname>Kipshidze</surname><given-names>NN</given-names></name><etal/></person-group><article-title>Contrast-induced nephropathy after percutaneous coronary
interventions in relation to chronic kidney disease and hemodynamic
variables</article-title><source>Am J Cardiol</source><year>2005</year><volume>95</volume><issue>1</issue><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">15619387</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagur</surname><given-names>R</given-names></name><name><surname>Webb</surname><given-names>JG</given-names></name><name><surname>Nietlispach</surname><given-names>F</given-names></name><name><surname>Dumont</surname><given-names>E</given-names></name><name><surname>De Larochelli&#x000e8;re</surname><given-names>R</given-names></name><name><surname>Doyle</surname><given-names>D</given-names></name><etal/></person-group><article-title>Acute kidney injury following transcatheter aortic valve
implantation: predictive factors, prognostic value, and comparison with
surgical aortic valve replacement</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><issue>7</issue><fpage>865</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">20037180</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kappetein</surname><given-names>AP</given-names></name><name><surname>Head</surname><given-names>SJ</given-names></name><name><surname>Genereux</surname><given-names>P</given-names></name><name><surname>Piazza</surname><given-names>N</given-names></name><name><surname>van Mieghem</surname><given-names>NM</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Updated standardized endpoint definitions for transcatheter
aortic valve implantation: the Valve Academic Research Consortium-2
consensus document</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><issue>19</issue><fpage>2403</fpage><lpage>2418</lpage><pub-id pub-id-type="pmid">23026477</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vahanian</surname><given-names>A</given-names></name><name><surname>Alfieri</surname><given-names>O</given-names></name><name><surname>Andreotti</surname><given-names>F</given-names></name><name><surname>Antunes</surname><given-names>MJ</given-names></name><name><surname>Bar&#x000f3;n-Esquivias</surname><given-names>G</given-names></name><name><surname>Baumgartner</surname><given-names>H</given-names></name><etal/><collab>ESC Committee for Practice Guidelines (CPG)</collab><collab>Joint Task Force on the Management of Valvular Heart Disease of the
European Society of Cardiology (ESC)</collab></person-group><article-title>European Association for Cardio-Thoracic Surgery (EACTS):
Guidelines on the management of valvular heart disease (version 2012): the
Joint Task Force on the Management of valvular heart disease of the European
Society of Cardiology (ESC) and the European Association for Cardio-Thoracic
Surgery (EACTS)</article-title><source>Eur J Cardiothorac Surg</source><year>2012</year><volume>42</volume><issue>4</issue><fpage>S1</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">22922698</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elhmidi</surname><given-names>Y</given-names></name><name><surname>Bleiziffer</surname><given-names>S</given-names></name><name><surname>Deutsch</surname><given-names>MA</given-names></name><name><surname>Krane</surname><given-names>M</given-names></name><name><surname>Mazzitelli</surname><given-names>D</given-names></name><name><surname>Lange</surname><given-names>R</given-names></name><etal/></person-group><article-title>Acute kidney injury after transcatheter aortic valve
implantation: incidence, predictors and impact on mortality</article-title><source>Arch Cardiovasc Dis</source><year>2014</year><volume>107</volume><issue>2</issue><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">24556191</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najjar</surname><given-names>M</given-names></name><name><surname>Salna</surname><given-names>M</given-names></name><name><surname>George</surname><given-names>I</given-names></name></person-group><article-title>Acute kidney injury after aortic valve replacement: incidence,
risk factors and outcomes</article-title><source>Expert Rev Cardiovasc Ther</source><year>2015</year><volume>13</volume><issue>3</issue><fpage>301</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">25592763</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genereux</surname><given-names>P</given-names></name><name><surname>Kodali</surname><given-names>SK</given-names></name><name><surname>Green</surname><given-names>P</given-names></name><name><surname>Paradis</surname><given-names>JM</given-names></name><name><surname>Daneault</surname><given-names>B</given-names></name><name><surname>Rene</surname><given-names>G</given-names></name><etal/></person-group><article-title>Incidence and effect of acute kidney injury after transcatheter
aortic valve replacement using the new valve academic research consortium
criteria</article-title><source>Am J Cardiol</source><year>2013</year><volume>111</volume><issue>1</issue><fpage>100</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">23040657</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thongprayoon</surname><given-names>C</given-names></name><name><surname>Cheungpasitporn</surname><given-names>W</given-names></name><name><surname>Srivali</surname><given-names>N</given-names></name><name><surname>Ungprasert</surname><given-names>P</given-names></name><name><surname>Kittanamongkolchai</surname><given-names>W</given-names></name><name><surname>Greason</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Acute kidney injury after transcatheter aortic valve replacement:
a systematic review and meta-analysis</article-title><source>Am J Nephrol</source><year>2015</year><volume>41</volume><issue>4-5</issue><fpage>372</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">26113391</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mack</surname><given-names>MJ</given-names></name><name><surname>Leon</surname><given-names>MB</given-names></name><name><surname>Smith</surname><given-names>CR</given-names></name><name><surname>Miller</surname><given-names>DC</given-names></name><name><surname>Moses</surname><given-names>JW</given-names></name><name><surname>Tuzcu</surname><given-names>EM</given-names></name><etal/></person-group><article-title>5-year outcomes of transcatheter aortic valve replacement or
surgical aortic valve replacement for high surgical risk patients with
aortic stenosis (PARTNER 1): a randomised controlled trial</article-title><source>Lancet</source><year>2015</year><volume>385</volume><issue>9986</issue><fpage>2477</fpage><lpage>2484</lpage><pub-id pub-id-type="pmid">25788234</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherner</surname><given-names>M</given-names></name><name><surname>Wahlers</surname><given-names>T</given-names></name></person-group><article-title>Acute kidney injury after transcatheter aortic valve
implantation</article-title><source>J Thorac Dis</source><year>2015</year><volume>7</volume><issue>9</issue><fpage>1527</fpage><lpage>1535</lpage><pub-id pub-id-type="pmid">26543598</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudnick</surname><given-names>MR</given-names></name><name><surname>Kesselheim</surname><given-names>A</given-names></name><name><surname>Goldfarb</surname><given-names>S</given-names></name></person-group><article-title>Contrast-induced nephropathy: how it develops, how to prevent
it</article-title><source>Cleve Clin J Med</source><year>2006</year><volume>73</volume><issue>1</issue><fpage>75</fpage><lpage>80</lpage><comment>83-7</comment><pub-id pub-id-type="pmid">16444919</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XC</given-names></name><name><surname>Fu</surname><given-names>XH</given-names></name><name><surname>Wang</surname><given-names>YB</given-names></name><name><surname>Jia</surname><given-names>XW</given-names></name><name><surname>Wu</surname><given-names>WL</given-names></name><name><surname>Gu</surname><given-names>XS</given-names></name><etal/></person-group><article-title>Prediction of contrast-induced nephropathy in diabetics
undergoing elective percutaneous coronary intervention: role of the ratio of
contrast medium volume to estimated glomerular filtration
rate</article-title><source>Chin Med J</source><year>2011</year><volume>124</volume><issue>6</issue><fpage>892</fpage><lpage>896</lpage><pub-id pub-id-type="pmid">21518598</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gul</surname><given-names>I</given-names></name><name><surname>Zungur</surname><given-names>M</given-names></name><name><surname>Tastan</surname><given-names>A</given-names></name><name><surname>Okur</surname><given-names>FF</given-names></name><name><surname>Damar</surname><given-names>E</given-names></name><name><surname>Uyar</surname><given-names>S</given-names></name><etal/></person-group><article-title>The importance of contrast volume/glomerular filtration rate
ratio in contrast-induced nephropathy patients after transcatheter aortic
valve implantation</article-title><source>Cardiorenal Med</source><year>2015</year><volume>5</volume><issue>1</issue><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">25759698</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbieri</surname><given-names>L</given-names></name><name><surname>Verdoia</surname><given-names>M</given-names></name><name><surname>Marino</surname><given-names>P</given-names></name><name><surname>Suryapranata</surname><given-names>H</given-names></name><name><surname>De Luca</surname><given-names>G</given-names></name><collab>Novara Atherosclerosis Study Group</collab></person-group><article-title>Contrast volume to creatinine clearance ratio for the prediction
of contrast-induced nephropathy in patients undergoing coronary angiography
or percutaneous intervention</article-title><source>Eur J Prev Cardiol</source><year>2016</year><volume>23</volume><issue>9</issue><fpage>931</fpage><lpage>937</lpage><pub-id pub-id-type="pmid">26525064</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobson</surname><given-names>CE</given-names></name><name><surname>Yavas</surname><given-names>S</given-names></name><name><surname>Segal</surname><given-names>MS</given-names></name><name><surname>Schold</surname><given-names>JD</given-names></name><name><surname>Tribble</surname><given-names>CG</given-names></name><name><surname>Layon</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Acute kidney injury is associated with increased long-term
mortality after cardiothoracic surgery</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>18</issue><fpage>2444</fpage><lpage>2453</lpage><pub-id pub-id-type="pmid">19398670</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loutzenhiser</surname><given-names>R</given-names></name><name><surname>Griffin</surname><given-names>K</given-names></name><name><surname>Williamson</surname><given-names>G</given-names></name><name><surname>Bidani</surname><given-names>A</given-names></name></person-group><article-title>Renal autoregulation: new perspectives regarding the protective
and regulatory roles of the underlying mechanisms</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2006</year><volume>290</volume><issue>5</issue><fpage>R1153</fpage><lpage>R1167</lpage><pub-id pub-id-type="pmid">16603656</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panwar</surname><given-names>R</given-names></name><name><surname>Lanyon</surname><given-names>N</given-names></name><name><surname>Davies</surname><given-names>AR</given-names></name><name><surname>Bailey</surname><given-names>M</given-names></name><name><surname>Pilcher</surname><given-names>D</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name></person-group><article-title>Mean perfusion pressure deficit during the initial management of
shock: an observational cohort study</article-title><source>J Crit Care</source><year>2013</year><volume>28</volume><issue>5</issue><fpage>816</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">23849541</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostermann</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name><name><surname>Crichton</surname><given-names>S</given-names></name></person-group><article-title>Low mean perfusion pressure is a risk factor for progression of
acute kidney injury in critically ill patients: a retrospective
analysis</article-title><source>BMC Nephrol</source><year>2017</year><volume>18</volume><issue>1</issue><fpage>151</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">28468613</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuis</surname><given-names>RJ</given-names></name><name><surname>Rod&#x000e9;s-Cabau</surname><given-names>J</given-names></name><name><surname>Sinning</surname><given-names>JM</given-names></name><name><surname>van Garsse</surname><given-names>L</given-names></name><name><surname>Kefer</surname><given-names>J</given-names></name><name><surname>Bosmans</surname><given-names>J</given-names></name><etal/></person-group><article-title>Blood transfusion and the risk of acute kidney injury after
transcatheter aortic valve implantation</article-title><source>Circ Cardiovasc Interv</source><year>2012</year><volume>5</volume><issue>5</issue><fpage>680</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">23048055</pub-id></element-citation></ref></ref-list></back></article>